



## **Idera Pharmaceuticals to Host Conference Call and Webcast to Report Second Quarter 2014 Financial Results**

**August 5, 2014 12:00 PM EDT**

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 5, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and orphan diseases, today announced that the Company will host a conference call and live audio webcast at 8:30 a.m. EDT on Tuesday, August 12, 2014 to report its second quarter 2014 financial results and provide a corporate update.

In order to participate in the conference call, please dial 1-800-901-5241 (domestic) or 1-617-786-2963 (international) and provide the access code 28510971. The live webcast can be accessed under "Investor Events" in the Investors section of the Company's website at [www.iderapharma.com](http://www.iderapharma.com).

A replay of the call will be available at 1:30 p.m. EDT on August 12, 2014 until 11:59 p.m. EDT on August 19, 2014. To access the replay, please dial 1-888-286-8010 (domestic) or 1-617-801-6888 (international) and reference the access code 67213242. The archived webcast will be available for 90 days in the Investors section of Idera's website at [www.iderapharma.com](http://www.iderapharma.com).

### **About Idera Pharmaceuticals, Inc.**

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and orphan autoimmune diseases. Idera's proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like Receptors (TLRs). In addition to its TLR programs, Idera is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA.

Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals, Inc.  
Lou Arcudi, 617-679-5517  
[larcudi@iderapharma.com](mailto:larcudi@iderapharma.com)